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ABSTRACT Reduced circulating levels of a -antitrypsin
(ajAT) are associated with certain ajAT genotypes and in-
creased susceptibility to emphysema. Unfortunately, the
amounts of ajAT that would be required for replacement
therapy are beyond the capacity of plasma fractionation and
mammalian cell culture systems. Thus, we have examined the
potential of transgenic animals as an alternative means of
producing human ajAT. A hybrid gene constructed by using
sequences from the ovine milk protein gene P-lactoglobulin
fused to an ajAT "minigene" was used to generate transgenic
mice. Of 13 independent transgenic mice and mouse lines, 5
expressed the hybrid gene in the mammary gland, 5 in the
salivary glands, and 2 in both these tissues. Human ajAT was
secreted into the milk of each of the 7 mice and mouse lines that
expressed the hybrid gene in the mammary gland. Four of these
mammary-expressing transgenic mice and mouse lines pro-
duced concentrations of at least 0.5 mg of ajAT per ml in their
milk; one line (AATB 35) produced 7 mg of this protein per ml.
ajAT from transgenic mouse milk was similar in size to human
plasma-derived ajAT and showed a similar capacity to inhibit
trypsin. Expression at equivalent levels in transgenic sheep or
cattle would yield sufficient ajAT for therapeutic purposes.
Genetic deficiencies of a1-antitrypsin (a1AT) in humans are
common and result in an increased susceptibility to emphy-
sema (1). Human a1AT is a 394-amino acid glycoprotein that
acts as a suicide inhibitor of a wide range of serine proteases.
In humans, the ajAT gene is expressed in a variety of tissues,
including macrophages, kidney, small intestine, pancreas,
and liver; the latter is the primary site of expression (1, 2). In
normal humans, more than 2 g of a1AT is synthesized daily,
resulting in a serum concentration of -2 mg/ml.
The primary function of ajAT is to inhibit neutrophil
elastase and thus prevent this protease from causing exces-
sive tissue damage (1). The S and Z a1AT alleles are relative-
ly common (-0.03 and 0.02, respectively) and encode pro-
teins that have reduced stability (S) or are poorly secreted
(Z), although they exhibit normal antiprotease activity. In-
dividuals with the SZ and ZZ genotypes have significantly
reduced concentrations ofa1AT (<0.8 mg/ml) and are at risk
of developing the degenerative lung disease emphysema,
particularly if they smoke.
Since ajAT normally circulates at 2 mg/ml and has a
half-life of6 days, considerable quantities (=4 g per week per
patient) would be required for replacement therapy for af-
flicted individuals (3), which amounts to 4000-8000 kg an-
nually to treat the ZZ homozygote population of the United
States (4). Such large amounts of protein will be available
only if recombinant DNA technology is used for production.
However, although a1AT does not require its carbohydrate
side chains for activity, the in vivo half-life of nonglycosyl-
ated alAT (expressed in yeast) is 50-fold lower than that of
plasma-derived a1AT (4). Therefore it would seem prudent to
produce alAT in a mammalian expression system capable of
making the appropriate posttranslational modifications. Un-
fortunately, large-scale culture of mammalian cells is expen-
sive and technically demanding and thus far has failed to
match the yields necessary for high dosage therapeutics, as
exemplified by a1AT.
As an alternative to genetically engineered cell lines,
Palmiter et al. (5) proposed that valuable proteins could be
harvested from transgenic animals. We have argued that the
mammary gland is the organ of choice for the expression of
recombinant proteins (6, 7) because large amounts of protein
can be synthesized by the mammary gland, secreted into
milk, and collected easily without detriment to the animal.
We have decided to use sheep for this purpose and have
recently demonstrated the production ofhuman factor IX and
a1AT in the milk of transgenic sheep (8, 9). In these sheep,
and also in transgenic mice carrying the same hybrid genes,
the levels of expression of the transgenes were low. The
comparisons of the performance of these hybrid genes (FIXA
and AATA) in transgenic sheep and mice are the subject of
separate studies (M.M., A.L.A., S. Harris, J.P.S., B. White-
law, I. Wilmut, and A.J.C., unpublished results; M.M., H.
Bessos, C. Prowse, J.P.S., B. Whitelaw, I. Wilmut, and
A.J.C., unpublished results).
As money and time preclude the use of large animals to test
and refine DNA constructs for efficient expression, we have
elected to carry out these experiments in transgenic mice. We
previously showed that the gene encoding a sheep milk
protein, 8-lactoglobulin (BLG), was expressed efficiently
and abundantly in the mammary gland of transgenic mice
(10). Here we show that sequences derived from this gene can
be used to direct expression ofhuman a1AT sequences in the
mammary gland, yielding high levels of human a1AT in milk.
METHODS
Hybrid Gene Construction and Production of Transgenic
Mice. A hybrid gene (referred to as AATB, see Fig. 1) was
elaborated in which the Pvu II site within the 5' untranslated
sequences of the ovine BLG clone SS1 (11, 12) was fused to
the Taq I site in the 5' untranslated sequences of a1AT. The
first a1AT intron was excluded by using DNA sequences
from a cDNA clone, p8alppg, which encodes the M1 variant
of a1AT (13), as the source of the first 80 base pairs of a1AT
sequences, extending up to the BamHI site in the second
exon. The remainder of the alAT "minigene" comprises a
Abbreviations: ajAT, a1-antitrypsin; BLG, 3-lactoglobulin; G, gen-
eration n; RID, radial immunodiffusion.
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6.5-kilobase (kb) BamHI fragment from the human a1AT
genomic clone pATp7 [also encoding the M1 variant of a1AT
(14)]. The construct was elaborated in the vector pPOLYIII-I
(15), enabling excision of the 10.6-kb insert by using Not I
sites in the polylinker sequences. Gel-purified insert DNA
was microinjected into pronuclear mouse eggs [collected
from (C57BL/6 x CBA)F1 mice after mating with F1 stud
males] in order to generate transgenic mice (10, 16). Lines
were propogated by mating with F1 mice.
DNA and RNA Analysis. DNA (for Southern blot analysis)
prepared from tail biopsies was digested with restriction
enzyme(s), subjected to agarose gel electrophoresis, blotted
to Hybond N (Amersham) nylon membranes, and probed
with 32P-labeled AATB DNA sequences. RNA was prepared
from lactating mice 11 days after parturition by standard
methods (17, 18). Aliquots (10 /ig) of total RNA were
fractionated on denaturing Mops/formaldehyde (1-1.5%)
agarose gels, transferred to Hybond N membranes (Amer-
sham), and probed with a 32P-labeled 243-base-pair Taq I-Pst
I fragment derived from the 3' end of p8alppg (13), which
allows mouse and human a1AT mRNAs to be distinguished.
DNA probes were labeled by using random primers (19), and
hybridizations were carried out as described by Church and
Gilbert (20).
Analysis of Milk. Milk was collected from lactating females
11 days after parturition as described by Simons et al. (10).
Mouse milk was diluted 1:5 in distilled water, and fat was
removed after centrifugation. To prepare whey, 1.0 M HCI
was added to give a final pH of 4.5, to precipitate the caseins,
which were then removed by centrifugation.
Diluted milk or whey samples were solubilized by boiling
in loading buffer prior to discontinuous SDS/polyacrylamide
(8% or 10%) gel electrophoresis (21) and immunoblotting
analysis (22). Human a1AT was identified on immunoblot
filters by using goat anti-a1AT serum [Protein Reference Unit
(PRU), Royal Hallamshire Hospital, Sheffield S10 2JF] and
anti-sheep/goat IgG serum conjugated to horseradish perox-
idase [Scottish Antibody Production Unit (SAPU), Law
Hospital, Carluke, Lanarkshire, ML8 5ES]. Amounts of
human a1AT in mouse milk were measured by radial
immunodiffusion (RID) and radioimmunoassay (RIA). RID
estimates were obtained by using LC-Partigen RID plates
(Behring Diagnostics) according to the manufacturer's in-
structions. RIAs were performed according to standard pro-
cedures (23) with goat anti-human a1AT antiserum (PRU) and
donkey anti-goat IgG (SAPU). Human a1AT, purified from
plasma by using a modification of the method described by
Laurell et al. (24), was iodinated by using chloramine T and
used as the tracer, and pooled human plasma was employed
for calibration. The detection limits of these methods were 40
,g/ml (RID) and 5 ,g/ml (RIA), respectively, when applied
to defatted murine milk samples, and results were validated
by using known amounts of human plasma/serum added to
control mouse milk.
Trypsin Inhibitory Activity. Dilutions of defatted milk or
plasma (40 ,l) were incubated at room temperature with
SalI
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FIG. 1. The AATB construct comprises -4.0 kb of the 5' end of
the ovine BLG clone SS1 (11, 12) fused to a minigene encoding
human a1AT. Thick line, 5' BLG sequences; open box, BLG exon
1 sequences; hatched boxes, a1AT exons; thin lines, a1AT introns
and 3' flanking regions. The position of the BLG TATA box and also
the a1AT initiation codon, stop codon, and polyadenylylation site are
shown.
equal volumes of trypsin (bovine pancreatic type III, Sigma)
at 200 units/ml in 0.1 M Tris/0.15 M NaCl/3 mM sodium
azide, pH 8.0 for 5 min, before addition of 40 ,ul of chro-
mogenic substrate S-2222 (KabiVitrum) (25). After 2.5 min,
acetic acid was added to a final concentration of 8.5% to stop
the reaction, and absorbances at 405 nm were read immedi-
ately.
RESULTS
Generation of Transgenic Mice. To direct expression of
a1AT to the mammary gland oftransgenic mice, a hybrid gene
(AATB) was elaborated, comprising, -4.0 kb of the 5' end of
the ovine BLG gene fused to a minigene encoding human
a1AT (Fig. 1). The hybrid gene (AATB) was microinjected
into pronuclei of fertilized mouse eggs (n = 993). Analysis of
DNA prepared from tail biopsies showed that 21 of the 122
generation zero (GO) animals carried the AATB construct.
Expression of the AATB Transgene. Expression of the
transgene was assessed by analyzing RNA and milk from
lactating females that were generally either Go animals or the
transgenic G1 offspring of Go males. Three patterns ofhuman
a1AT RNA expression were observed after Northern blot
analysis (Fig. 2). In some animals and lines, expression was
limited to the mammary gland, whereas in others it was
confined to the salivary gland. There were two lines where
transcripts were seen in both the mammary and the salivary
glands (Table 1). As judged by comparison with human liver
RNA and HepG2 RNA, both mammary and salivary tran-
scripts were, as expected, the same size as human liver a1AT
mRNA. One line in particular, AATB 35, showed extremely
high levels of expression of a1AT mRNA in the mammary
gland, comparable to the level observed in human liver.
Production of Human a1AT in Milk. Milk was analyzed by
SDS/PAGE and immunoblotting for the presence of human
a1AT protein (Fig. 3a). Human a1AT was present in milk
from all the transgenic animals that had detectable levels of
human a1AT mRNA in the mammary gland but was not
detected in those that did not express the transgene or
expressed it only in the salivary gland. The antiserum to
human a1AT cross-reacted with an endogenous mouse pro-
tein present in milk, probably murine a1AT. The most
CM 35.3 26.1 17.20
HL - M L Sp K Sa M L Sp K Sa M L Sp K Sa M L Sp K Sa - HG
I. a.
FIG. 2. Northern blot analysis oftotal RNAfromtransgenic mice (numbers AATB 35.3, AATB 26.1, and AATB 17.20) and acontrol C57BL/6
mouse (CM). The tissues analyzed were mammary (M), liver (L), spleen (Sp), kidney (K), and salivary (Sa). Control lanes: HL, human liver
RNA; HG, HepG2 RNA (26). The "1400-nucleotide a1AT transcripts are indicated by an arrow. Ten micrograms of total RNA was loaded except
for HL, 35.3 M, and HG, which contain 1 ,ug of sample RNA with 9 ,ug of control mouse mammary RNA.
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Table 1. Summary of the pattern of expression of AATB RNA
in transgenic mice
Animal/line Sex* Copy no. Mammary Salivary
15 M 3 +t-
17 M 10 + +
26 M 20 - +
28 M 3 - -
35 M 1 + +
44 F 15 + -
45 F 2 +
65 F 3 + -
69 F 2 + -
78 M 10 - +
79 M 15 - +
105 F 20 - +
107 F 15 - +
Expression was analyzed by Northern blot analysis of tissues from
lactating Go females or, where the founder was male, from G, females
that had inherited the transgene. No human a1AT RNA was detected
in liver, spleen, kidney, or heart. Copy numbers were estimated by
Southern blotting relative to copy number controls.
*Sex of the Go animals.
ta1AT transcripts were detected only in poly(A)+ RNA in one oftwo
animals analyzed.
prominent human a1AT bands in transgenic mouse milk had
electrophoretic mobilities similar, but not identical, to the
major bands observed in samples of purified human a1AT or
pooled human plasma.
The concentrations of human a1AT in transgenic mouse
milk were measured by RID and RIA (Table 2). The results
obtained with the two methods of measurement were similar.
Concentrations ranged from 6 pug/ml (mouse 15.20) to more
than 7 mg/ml (mouse 35.3). Of the seven animals and lines
that expressed the transgene in the mammary gland, four
yielded concentrations of a1AT of at least 0.5 mg/ml.
Milk from Transgenic Mice Has Enhanced Trypsin-
Inhibitory Activity. Milk samples from line AATB 35 were
shown to have high levels of trypsin-inhibitory activity when
compared with milk from nontransgenic mice (Fig. 4a). When
milk from line AATB 35 mice was compared with human
plasma, it was evident that equivalent amounts ofplasma and
milk a1AT had similar biological activities (Fig. 4b). Milk
from line AATB 17 mice was also shown to have greater
levels of antitrypsin activity than milk from control mice. The
trypsin-inhibitory capacities ofmilk from lines 17 and 35 were
in accord with expectations based on the a1AT contents of
these milks as measured by immunological methods.
DISCUSSION
For the reasons outlined above, we sought to harness the high
protein synthetic capacity of the mammary gland of trans-
genic animals as a source of recombinant a1AT. To this end,
we elaborated a hybrid gene (AATB) by fusing the promoter
and 5' flanking sequences from the abundantly expressed
ovine milk protein BLG to a human a1AT minigene. The
construction of such hybrid genes and their excision from
vectors is eased if the component sequences are kept as short
as possible. However, introns have been found to be impor-
tant for the expression of transgenes (ref. 27; B. Whitelaw,
M.M., A.L.A., S. Harris, J.P.S., and A.J.C., unpublished
results). Nevertheless, the deletion ofsome intron(s) may still
allow high-level expression while facilitating transgene con-
struction. The omission ofthe first a1AT (5.3-kb) intron made
the elaboration of the construct simpler and excluded a
429-base-pair open reading frame, an Alu repeat, and a
pseudo transcription initiation sequence (28).
a
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FIG. 3. Electrophoretic analysis of milk proteins. (a) Immuno-
blot. Wheys, equivalent to 1.5 ,ul of milk, from transgenic mice
(numbered lanes) and control mice (CM), 0.25 ug of purified human
ajAT (AT) (Sigma), and 0.05 pi of pooled human sera (H) were
immunoblotted and probed for human a1AT. (b) SDS/PAGE gel.
Defatted milk and whey samples from control mice (CM) and two
transgenic G1 females from line 35 (numbered lanes) were electro-
phoresed alongside dilutions of purified human ajAT (Sigma; lane 1,
5 ,Ag; lane 2, 2.5 ,tg; lane 3, 1 ,Ag) and molecular weight markers (M)(GIBCO, BRL) and stained with Coomassie blue.
The finding of mammary gland expression of the AATB
construct in seven transgenic individuals and lines confirmed
the efficacy of the construct design. However, salivary
expression using the BLG promoter was not anticipated. We
Table 2. Measurements of human a1AT present in transgenic
mouse milk as determined by immunoblotting (Blot), RID,
and RIA
RID, RIA,
Animal/line Generation Blot Ag/ml (n) /g/ml
15.10 G1 + -(1) 6
15.20 G1 - (1)
17.23 G1 + 463 (5) ND
17.24 G1 + 556 (6) 520
17.5.1 G2 + 990 (2) 1055
17.5.4 G2 + 407 (2) 390
17.5.9 G2 + 606 (3) 490
17.5.16 G2 + 730 (2) 680
35.3 G1 + 7738 (2) 9000
35.11 G1 + 6215 (2) 5700
44 Go + 879 (2) 920
45 Go + 84 (2) 59
65 Go + 83 (2) 46
69 Go + 695 (2) 445
n, Number of assays performed; ND, not determined.
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FIG. 4. Trypsin-inhibitory activity of transgenic mouse milk. (a) A comparison of the trypsin-inhibitory capacities of milk from transgenic
mouse AATB 35.11 and pooled milk from nontransgenic mice. (b) A comparison of the trypsin-inhibitory capacities of the human a1AT in milk
from mouse AATB 35.11 and in pooled human plasma; the human ajAT contents of the diluted milk and plasma samples were calculated from
RID estimates of the concentrations of the corresponding milk and plasma.
eliminated mammary gland contamination of salivary gland
RNA as the cause of this result by reprobing with mammary-
specific probes (data not shown). We have not detected
significant salivary expression of a variety of other trans-
genes comprising the BLG gene or its hybrid derivatives (ref.
10; A.J.C., A.L.A., S. Harris, M.M., J.P.S., and B. White-
law, unpublished observations). All these other transgenes
share 3' BLG sequences that are absent from the AATB
construct. Interestingly, transgenic mice carrying the human
a1AT gene show expression in the salivary gland (29). Several
other groups have also reported salivary gland expression of
hybrid genes in which the promoter and 5' flanking sequences
were also derived from mammary-specific genes (30-33).
Thus, it is possible that the downstream BLG sequences
contain a salivary gland-specific negative regulatory element
or that positive regulatory elements within the a1AT se-
quences direct expression to this tissue.
Although the electrophoretic mobilities, in SDS/PAGE, of
a1AT from transgenic mouse milk or human plasma are
similar, the electrophoretic pattern of a1AT proteins ob-
served in transgenic mouse milk appears more complex. This
may reflect differences in the posttranslational modifications
ofthe proteins produced in human liver and mouse mammary
gland. Alternatively, human a1AT produced in mouse milk
may be more susceptible to degradation during secretion or
storage.
Within lines of transgenic mice, some variation in expres-
sion was observed. In line 15, low-level a1AT expression was
detected in only one of the two animals analyzed, and in line
17, in which both G1 and G2 animals were analyzed, an
-2-fold variation in a1AT concentration was observed. This
may simply reflect a variation in the total protein content of
individual milk samples (10) or variation in the level of
transgene expression within a line due to nonuniform genetic
backgrounds. We have also noted considerable variation in
the level of transgene expression within a line of mice
carrying the BLG gene (M.M., unpublished observations).
The level of human a1AT in the milk of line 35 mice is very
high, as expected from the level of ajAT mRNA observed in
the mammary gland. The a1AT is clearly evident on
Coomassie blue-stained gels of total milk proteins (Fig. 3b).
Densitometry of stained gels showed that human a1AT
comprises 10% of total milk proteins and more than 30o of
the whey proteins. These proportions compare favorably
with those obtained for expression of a1AT in bacteria (15%
of total cell protein) and yeast (3% of total soluble proteins)
and particularly so when compared with eukaryotic cell
culture expression (<1 tug per 106 cells per 24 hr) (34-37).
The human a1AT present in the milk of transgenic mice
from lines 17 and 35 was shown to be biologically active in a
trypsin-inhibition assay. When transgenic mouse milk
(mouse 35.11) and pooled human plasma were compared, it
was evident that equivalent amounts of plasma and recom-
binant a1AT had similar capacities to inhibit trypsin (Fig. 4b),
indicating that a1AT synthesized in the mammary gland and
secreted into milk is as biologically active as that derived
from plasma.
In December 1987, the U.S. Food and Drug Administration
licensed the use of a1AT in replacement therapy (1). The
methods by which a1AT might be delivered to the critical lung
locations include intravenous infusions, aerosol sprays, and
gene therapy (38, 39). It seems likely that gene therapy will
be very expensive and not readily available to the many
individuals suffering from a1AT deficiency. For replacement
therapy by means of aerosols or intravenous infusions to be
generally available, large quantities of biologically active and
correctly glycosylated a1AT will be required.
In this paper we have described the production of trans-
genic mice expressing high levels of biologically active hu-
man a1AT in their milk. The levels of expression in line 35 are
of particular interest and, to our knowledge, represent one of
the highest levels of expression of a recombinant protein in
any mammalian expression system, including transgenic
mice and sheep (9, 40, 41). High-milk-yielding breeds of
sheep, such as the East Friesland, can produce up to 400 liters
per lactation. Therefore transgenic sheep that express a1AT
at the levels observed in line 35 could produce up to 3 kg of
a1AT at each lactation, a level of production that might be
capable of supplying the large quantities required for replace-
ment therapy.
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